How Stewart was paid
$1.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Total |
|---|---|---|---|---|---|
| Richard StewartFormer Chief Executive Officer | $615,000 | $522,900 | — | $230,625 | $1,368,525 |
| Erik AtkissonChief Legal Officer | $130,255 | $853,148 | — | — | $983,403 |
| Jaime XinosFormer Chief Commercial Officer | $450,000 | $311,000 | $48,601 | $135,000 | $944,601 |
What changed and why
- $1.4M$1,368,525 was Richard Stewart’s 2025 total compensation, down from $1,735,552 in 2024.
- 75%75% of 2025 corporate performance objectives were achieved, determining the annual incentive payouts.
- 50%50% of base salary was Stewart’s target bonus; Xinos’ target bonus was 40% of base salary.
- 157,500 performance stock units were granted to Stewart, tied to FDA-related cytisinicline milestones.
- 250,000 stock options were granted to Atkisson as an employment inducement.
- 2025 goals included FDA NDA acceptance, commercial readiness, and cytisinicline launch activities.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.